Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | TOURMALINE-MM3: undetectable MRD as an endpoint for maintenance therapy

Bruno Paiva • 12 Jun 2020
EHA 2020
Multiple Myeloma Ixazomib
TOURMALINE-MM3

Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, discusses results from the TOURMALINE-MM3 study (NCT02181413) of ixazomib vs placebo maintenance therapy in newly diagnosed multiple myeloma patients. Interestingly, TOURMALINE-MM3 used undetectable minimal residual disease as the clinical endpoint for this trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Bruno Paiva

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
2:08
Minimally invasive assessment of MRD in multiple myeloma
Bruno Paiva • 9 Dec 2023
2:34
Mutant hematopoietic progenitor cells in MM associated with secondary primary malignancies
Bruno Paiva • 9 Dec 2023
1:52
Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers
Bruno Paiva • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals